Takeda offers a compelling investment case with six late-stage therapies targeting $20 billion in peak sales by 2030-31.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback